focus -WSS

focus

author：Wikipedia 2025-10-01 22:49:50 - browse：28644

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Readout Newsletter: Bluebird, CVS, Contineum

explore

WSS

Gene editing the human germline: What are the risks?

Judge sides with young activists in first

What to know about the judge who will handle the Trump case

Senators push IRS to launch nonprofit hospital probe

Mark Cuban is blaming the wrong people for high drug costs

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

hotspot

focus

explore

Supreme Court strikes down use of affirmative action

Maui wildfire now ranks as the fifth

The high cost of giving birth even with insurance

Nurses recount patients attacks

In Memoriam: Notable people who died in 2023

Senators push IRS to launch nonprofit hospital probe

Dobbs anniversary: the lost opportunity of abortion as health care

Virtual Event: March of the Biosimilars

United colonoscopy coverage change 'may cost lives,' doctors say

Stop the failed accountable care organization experiment

leisure time

Novo Nordisk touts Wegovy study, but still struggling with supply

Schizophrenia gene found to be linked to cells' energy dysfunction

Surge in Apellis stock fueled by confidence in safety of its eye drug

Biden administration begins canceling student loan debt for 804,000 borrowers

Methadone treatment changes are coming. Do they go far enough?

Surge in Apellis stock fueled by confidence in safety of its eye drug

knowledge

focus

focus

focus